|
| 37213438 | Long-Term Benefits from Early Antiretroviral Therapy Initiation in HIV Infection. | NEJM Evid | 2023 |
| 34557563 | Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study. | Open Forum Infectious Diseases | 2021 |
| 34127579 | Frequency of post treatment control varies by antiretroviral therapy restart and viral load criteria. | AIDS | 2021 |
| 34197772 | Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet HIV | 2021 |
| 31536120 | Prevalence, Incidence, and Clearance of Human Papillomavirus Types Covered by Current Vaccines in Men With Human Immunodeficiency Virus in the SUN Study. | Journal of Infectious Diseases | 2020 |
| 31149766 | Lower serum adiponectin level is associated with lipodystrophy among HIV-infected men in the Study to Understand the Natural History of HIV/AIDS in the Era of Effective Therapy (SUN) study. | HIV Medicine | 2019 |
| 30032171 | The Effect of Interrupted/Deferred Antiretroviral Therapy on Disease Risk: A SMART and START Combined Analysis. | Journal of Infectious Diseases | 2019 |
| 30852729 | HIV Care Trajectories as a Novel Longitudinal Assessment of Retention in Care. | AIDS and Behavior | 2019 |
| 29643240 | HIV Protease-Generated Casp8p41, When Bound and Inactivated by Bcl2, Is Degraded by the Proteasome. | J Virol | 2018 |
| 30085241 | The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies. | J Infect Dis | 2018 |
| 29452366 | Prevalence and Incidence of Anal and Cervical High-Risk Human Papillomavirus (HPV) Types Covered by Current HPV Vaccines Among HIV-Infected Women in the SUN Study. | Journal of Infectious Diseases | 2018 |
| 29211874 | Prevalence, Incidence, and Clearance of Anal High-Risk Human Papillomavirus Infection Among HIV-Infected Men in the SUN Study. | Journal of Infectious Diseases | 2018 |
| 28272164 | Brief Report: Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults. | Journal of acquired immune deficiency syndromes (1999) | 2017 |
| 28628632 | Increasing procaspase 8 expression using repurposed drugs to induce HIV infected cell death in ex vivo patient cells. | PLoS ONE | 2017 |
| 27559122 | Incidence of AIDS-Defining Opportunistic Infections in a Multicohort Analysis of HIV-infected Persons in the United States and Canada, 2000-2010. | J Infect Dis | 2016 |
| 27174191 | Duration of Influenza Virus Shedding Among HIV-Infected Adults in the cART Era, 2010-2011. | AIDS Research and Human Retroviruses | 2016 |
| 26268855 | Incidence and Predictors of Abnormal Anal Cytology Findings Among HIV-Infected Adults Receiving Contemporary Antiretroviral Therapy. | Journal of Infectious Diseases | 2016 |
| 26366785 | High Prevalence of Low Bone Mineral Density and Substantial Bone Loss over 4 Years Among HIV-Infected Persons in the Era of Modern Antiretroviral Therapy. | AIDS Research and Human Retroviruses | 2016 |
| 27610462 | Potential Impact of Integrating HIV Surveillance and Clinic Data on Retention-in-Care Estimates and Re-Engagement Efforts. | AIDS Patient Care and STDs | 2016 |
| 27609756 | Immediate Antiretroviral Therapy Reduces Risk of Infection-Related Cancer During Early HIV Infection. | Clinical Infectious Diseases | 2016 |
| 26424673 | Once-daily dolutegravir versus darunavir plus ritonavir for treatment-naive adults with HIV-1 infection (FLAMINGO): 96 week results from a randomised, open-label, phase 3b study. | Lancet HIV | 2015 |
| 25665269 | Turning the tide against AIDS by preventing new HIV infections initial experience with Minnesota's first PrEP clinic. | Minnesota Medicine | 2015 |
| 26133089 | Estimated glomerular filtration rates through 144â¿¿weeks on therapy in HIV-1-infected subjects receiving atazanavir/ritonavir and abacavir/lamivudine or simplified to unboosted atazanavir/abacavir/lamivudine. | HIV Clinical Trials | 2015 |
| 24508782 | Week 48 results from a randomized clinical trial of rilpivirine/emtricitabine/tenofovir disoproxil fumarate vs. efavirenz/emtricitabine/tenofovir disoproxil fumarate in treatment-naive HIV-1-infected adults. | AIDS | 2014 |
| 25393999 | Once-daily dolutegravir is superior to once-daily darunavir/ritonavir in treatment-naïve HIV-1-positive individuals: 96 week results from FLAMINGO. | J Int AIDS Soc | 2014 |
| 27050062 | Frailty and Pre-Frailty in a Contemporary Cohort of HIV-Infected Adults. | Journal of frailty & aging,The | 2014 |
| 24346640 | A randomized, double-blind comparison of single-tablet regimen elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus emtricitabine/tenofovir DF for initial treatment of HIV-1 infection: analysis of week 144 results. | Journal of acquired immune deficiency syndromes (1999) | 2014 |
| 24370480 | Immunologic predictors of coronary artery calcium progression in a contemporary HIV cohort. | AIDS | 2014 |
| 24813472 | Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection. | Journal of Infectious Diseases | 2014 |
| 24908550 | Switching to coformulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus continuation of non-nucleoside reverse transcriptase inhibitor with emtricitabine and tenofovir in virologically suppressed adults with HIV (STRATEGY-NNRTI): 48 week r | Lancet Infectious Diseases, The | 2014 |
| 23337366 | A randomized, double-blind comparison of coformulated elvitegravir/cobicistat/emtricitabine/tenofovir DF vs ritonavir-boosted atazanavir plus coformulated emtricitabine and tenofovir DF for initial treatment of HIV-1 infection: analysis of week 96 results | Journal of acquired immune deficiency syndromes (1999) | 2013 |
| 23362296 | SWIFT: prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed HIV-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen. | Clinical Infectious Diseases | 2013 |
| 23111762 | Disparities in prevalence of key chronic diseases by gender and race/ethnicity among antiretroviral-treated HIV-infected adults in the US. | Antiviral Therapy | 2013 |
| 22249305 | Prevalence and risk factors associated with herpes simplex virus-2 infection in a contemporary cohort of HIV-infected persons in the United States. | Sexually Transmitted Diseases | 2012 |
| 26223037 | Economic factors hamper HIV control efforts. | | 2012 |
| 22592834 | Routine brief risk-reduction counseling with biannual STD testing reduces STD incidence among HIV-infected men who have sex with men in care. | Sexually Transmitted Diseases | 2012 |
| 22748590 | Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir disoproxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double- | Lancet, The | 2012 |
| 22301072 | Effect of abacavir on acute changes in biomarkers associated with cardiovascular dysfunction. | Antiviral Therapy | 2012 |
| 22953476 | Antiretroviral medications as prevention: will the new paradigm reverse the HIV epidemic? | Minnesota Medicine | 2012 |
| 23199190 | Sadness in the SUN: using computerized screening to analyze correlates of depression and adherence in HIV-infected adults in the United States. | AIDS Patient Care and STDs | 2012 |
| 23094300 | A clinical view: a trio of HIV specialists offer their take on HIV--then, now, and in the future. Interview by Heidi M Nass. | Posit Aware | 2012 |
| 23082133 | Angiotensin converting enzyme inhibitor and HMG-CoA reductase inhibitor as adjunct treatment for persons with HIV infection: a feasibility randomized trial. | PLoS ONE | 2012 |
| 21480819 | Cystatin C and baseline renal function among HIV-infected persons in the SUN Study. | AIDS Research and Human Retroviruses | 2012 |
| 22183836 | Ongoing sexually transmitted disease acquisition and risk-taking behavior among US HIV-infected patients in primary care: implications for prevention interventions. | Sexually Transmitted Diseases | 2012 |
| 21860012 | Progression of carotid intima-media thickness in a contemporary human immunodeficiency virus cohort. | Clin Infect Dis | 2011 |
| 27652433 | Drug watch. Once-daily Nevirapine approved by FDA. | | 2011 |
| 27652432 | Inflammation and HIV--a complex tango. | | 2011 |
| 21217185 | High Prevalence of Echocardiographic Abnormalities among HIV-infected Persons in the Era of Highly Active Antiretroviral Therapy. | Clinical Infectious Diseases | 2011 |
| 21293992 | Factors associated with non-adherence to antiretroviral therapy in the SUN study. | AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV | 2011 |
| 20966828 | Human papillomavirus infection and cytologic abnormalities of the anus and cervix among HIV-infected women in the study to understand the natural history of HIV/AIDS in the era of effective therapy (the SUN study). | Sexually Transmitted Diseases | 2011 |